SPINK5 and Netherton syndrome: The loss of kallikrein inhibition via decreases in serine protease inhibitor Kazal type-5 (SPINK5) leads to Netherton syndrome, in which patients demonstrate impaired barrier function with epidermal hyperplasia and symptoms of atopic dermatitis [35].